安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Advanced and metastatic prostate cancer: ESMO Clinical . . .
This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
- TALZENNA Plus XTANDI Significantly Improves Radiographic . . .
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1 4 million new cases diagnosed globally in 2022 1 and 330,000 new cases anticipated in the United States in 2026 2 mCSPC, is a form of advanced prostate cancer that has spread beyond the prostate but is still sensitive to androgen inhibition 3 Despite recent
- Systemic Therapies for Metastatic Castration-Resistant . . .
The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide range of treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) In the past decade, new treatment options for mCRPC,
- Advanced Prostate Cancer: AUA SUO Guideline (2026)
The management of advanced prostate cancer is rapidly evolving To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to
- Prostate Cancer, Version 3. 2026, NCCN Clinical Practice . . .
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
- Metastatic castration-resistant prostate cancer (mCRPC)
Metastatic prostate cancer happens when the cancer spreads from the prostate to other parts of the body Sometimes the cancer spreads and hormone therapy helps control it This is called metastatic castration-sensitive prostate cancer (mCSPC) If the cancer spreads and no longer responds to hormone therapy medicines, it's considered mCRPC
- CUA Call-to-Action: Advanced Prostate Cancer (mCSPC) – 2026 . . .
Apply the latest guideline recommendations and evidence to optimize disease characterization and treatment selection in mCSPC Integrate advanced imaging, biomarker, and genetic testing into clinical decision-making to personalize therapy
- Chemotherapy-Forward Management of Advanced Prostate Cancer . . .
Taxane chemotherapy remains a durable backbone in advanced prostate cancer, but its clinical value is increasingly determined by timing, sequencing, and deliverability We synthesize pivotal randomized trials and contemporary guidance to provide a chemotherapy-forward framework spanning metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer
|
|
|